COMP <GO>
ILMN vs JNJ // ENTERPRISE SCALE & MARKET CAP
Illumina Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ILMN 2
— JNJ 11
▲ ENTERPRISE SCALE & MARKET CAP LEADER: JNJ
LAST: $235.99 (-18.64%) • MKT CAP: $43.80B
market-cap
$43.80B
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
market-cap
$662.49B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ILMN VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ILMN | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 66.10% | 67.90% | -1.80 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.20% | 25.50% | -7.30 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 47.5x | 18.5x | +29.00 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 2.13% | 2.97% | -0.84 | JNJ | /fcf-yield <GO> |
| Operating Margin | 18.60% | 34.70% | -16.10 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 19.60% | 28.50% | -8.90 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | -0.70% | 6.00% | -6.70 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.52 | 5.59 | +3.93 | ILMN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 7.20% | +0.20 | JNJ | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.6 | 60.4 | -21.77 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.16 | 1.08 | +0.08 | ILMN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 47.9x | 23.0x | +24.90 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $43.80B | $662.49B | -$618.69B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ILMN REV | JNJ REV | ILMN GROSS % | JNJ GROSS % | ILMN FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.34B | $94.19B | 66.1% | 67.9% | $931.0M | $19.70B |
| FY 2024 | $4.37B | $88.82B | 65.4% | 69.1% | $709.0M | $19.84B |
| FY 2023 | $4.50B | $85.16B | 44.0% | 44.0% | $275.3M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ILMN // BETA 1.16
JNJ // BETA 1.08